HBV Mutation Detail Information

> M204I Search Result


Mutation Information
Mutation Site M204I
Mutation Type Amino acid level
Gene/Protein/Region Type RT
Relevant Drug lamivudine (LAM);adefovir (ADV);telbivudine (LDT);entecavir (ETV)
Country Iran
Literature Information
PubMed PMID 23596461
Disease Hepatocellular carcinoma; Chronic hepatitis B; Liver cirrhosis; Acute hepatitis B; Fulminant hepatitis B
Published Year 2013
Journal Hepatitis monthly
Title Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naïve chronic HBV patients.
Author Mahabadi M,Norouzi M,Alavian SM,Samimirad K,Azad TM,Saberfar E,Mahmoodi M,Ramezani F,Karimzadeh H,Malekzadeh R,Montazeri G,Nejatizadeh A,Ziaee M,Abedi F,Ataei B,Yaran M,Sayad B,Hossein Somi M,Sarizadeh G,Sanei-Moghaddam I,Mansour-Ghanaei F,Rafatpanah H,Pourhosseingholi MA,Keyvani H,Kalantari E,Saberifiroozi M,Ali Judaki M,Ghamari S,Daram M,Fazeli Z,Goodarzi Z,Khedive A,Moradi A,Jazayeri SM
Evidence All strains belonging to genotype D.365 amino-acid substitutions were found. Mutations related to lamivudine, adefovir, telbivudine, and entecavir occurred in (YMDD) 4% (n = 13), (SVQ) 17.23% (n = 56), (M204I/V + L180M) 2.45% (n = 8) and (M204I) 2.76% (n = 9) of patients, respectively.

Contents
Description
Mutation Information Note
  • Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)
Literature Information Note
  • Evidence: sentence contains this mutation information in the citation